# Filing Detail

Form DEFR14A - Revised definitive proxy soliciting materials:
SEC Accession No. 0000950170-25-065795
Filing Date
2025-05-07
Accepted
2025-05-07 16:37:59
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFR14A | fulc_defr14a_2025.htm | DEFR14A | 30116
2 | GRAPHIC | img106926888_0.jpg | GRAPHIC | 1838177
3 | GRAPHIC | img106926888_1.jpg | GRAPHIC | 1215647
| Complete submission text file | 0000950170-25-065795.txt |  | 3870701

Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

EIN.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFR14A | Act: 34 | File No.: 001-38978 | Film No.: 25922079
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)